Status:

COMPLETED

Milligan-Morgan Versus Dearterialization With Mucopexy

Lead Sponsor:

Università degli Studi dell'Aquila

Conditions:

Hemorrhoids

Hemorrhoid Prolapse

Eligibility:

All Genders

18-80 years

Brief Summary

Nowadays, there are several methods that can be used for grade III hemorrhoidal disease, according to Goligher classificiation. Milligan Morgan hemorrhoidectomy is considered the most effective treatm...

Detailed Description

The study will be of a multicentre observational retrospective type. Any Italian Center belonging to the Italian Society of Colorectal Surgery (SICCR) in which at least 30 procedures are performed per...

Eligibility Criteria

Inclusion

  • ≥18 years-old
  • Goligher's grade III haemorrhoidal disease
  • indication to elective Doppler-guided or non-Doppler guided HAL surgery associated with mucopexy or Milligan-Morgan hemorrhoidectomy.

Exclusion

  • Recurrent disease
  • bleeding disorders
  • chronic inflammatory bowel diseases
  • vasculopathies
  • combined surgical techniques (HAL with mucopexy and removal of one or more haemorrhoidal nodules)

Key Trial Info

Start Date :

July 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 25 2021

Estimated Enrollment :

1000 Patients enrolled

Trial Details

Trial ID

NCT04863963

Start Date

July 1 2021

End Date

September 25 2021

Last Update

September 28 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Antonio Giuliani

L’Aquila, AQ, Italy, 67100